HENLIUS (02696) surged over 8% again, with an increase of 8.05% at the time of writing, reaching HK$69.8, and a turnover of HK$18.6408 million. On January 9th, at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), HENLIUS unveiled for the first time the Phase II proof-of-concept (POC) data for its PD-L1 ADC HLX43 in treating recurrent/metastatic esophageal squamous cell carcinoma (ESCC). This initial data release validates the therapeutic potential of HLX43 in pre-treated advanced ESCC patients, demonstrating encouraging efficacy and a favorable safety profile. HLX43 has shown consistent and sustained efficacy and safety trends across multiple solid tumor indications, including non-small cell lung cancer, cervical cancer, esophageal squamous cell carcinoma, and thymic carcinoma. Its broad-spectrum anti-tumor potential is being progressively confirmed through clinical practice, laying a crucial foundation for expanding into further indications. Notably, the 44th J.P. Morgan Healthcare Conference (JPM 2026) is scheduled for January 12–15 in San Francisco, USA. As one of the most influential annual gatherings in the global healthcare sector, the JPM conference is regarded as a vital window for global capital markets to observe trends in pharmaceutical innovation and the industry. Dr. Zhu Jun, Executive Director and CEO of HENLIUS, is set to deliver a keynote speech on January 15th local time, systematically sharing the company's latest progress and future blueprint with international investors and industry peers, focusing on HENLIUS's development path in its Globalization 2.0 phase, innovative pipeline layout, and medium-to-long-term strategic planning.